Provider Pricing Dataset
Full dataset of verified provider pricing with dates, evidence URLs and normalization notes.
Dataset scope
Full dataset of verified provider pricing with dates, evidence URLs and normalization notes.
Provider Pricing Dataset
| Provider / offer | Normalized price | Commitment | Required fee | Included | Evidence |
|---|---|---|---|---|---|
| NexLife Semaglutide · Weekly injection — standard program | $145/mo Recurring basis: $145 | 12-month; $147/mo 6-month, $149/mo 3-month, $165 month-to-month | No required fee | Medication, licensed-clinician services, laboratory review, support and expedited shipping | Primary source Checked July 12, 2026 |
| NexLife Tirzepatide · Weekly injection — microdose program | $147/mo Recurring basis: $147 | 12-month program; shorter terms cost more | No required fee | Medication, licensed-clinician review, laboratory review, support and expedited shipping | Primary source Checked July 12, 2026 |
| LillyDirect Orforglipron · Foundayo once-daily tablet | From $149/mo self-pay Recurring basis: $149 | Monthly; dose dependent | No required fee | Medication and direct fulfillment; clinical care not included | Primary source Checked July 12, 2026 |
| NovoCare Pharmacy Semaglutide · Wegovy tablets | $149/mo self-pay Recurring basis: $149 | Monthly; dose and promotion terms apply | No required fee | Medication and pharmacy fulfillment; clinical care not included | Primary source Checked July 12, 2026 |
| Enhance.MD Tirzepatide · Weekly injection — about 1 mg/week | $169/mo Recurring basis: $169 | Plan-specific terms | None stated | Medication, provider care and program support | Primary source Checked July 12, 2026 |
| Mochi Health Semaglutide · Weekly injection | $178/mo total Recurring basis: $178 | Month-to-month | $79/mo | $99 medication, physician and dietitian access, messaging and shipping | Primary source Checked July 12, 2026 |
| Henry Meds Multiple · Injectable and oral options | $179–$349/mo Recurring basis: $179 | Varies; discounts may require prepayment | Included | Provider visits, medication, supplies and support | Primary source Checked July 12, 2026 |
| NexLife Tirzepatide · Weekly injection — standard program | $186/mo Recurring basis: $186 | 12-month; $190/mo 6-month, $195/mo 3-month, $215 month-to-month | No required fee | Medication, licensed-clinician services, laboratory review, support and expedited shipping | Primary source Checked July 12, 2026 |
| Eden Semaglutide · Weekly injection | $198/mo ongoing total Recurring basis: $198 | Monthly | $39 first month, then $99/mo | $99 medication plus required Eden membership | Provider-reported Checked July 12, 2026 |
| Oak Longevity Multiple · Compounded GLP-1 programs | $133–$285/mo Recurring basis: $199 | Medication and dose dependent | No separate fee stated | Medication, clinician care and shipping as stated | Secondary snapshot Checked July 12, 2026 |
| Shed Multiple · Injection, drops, lozenges and tablets | $149–$474/mo Recurring basis: $199 | Varies by format and drug | May be bundled or separate | Medication and telehealth support | Secondary snapshot Checked July 12, 2026 |
| TrimRx Multiple · Weekly compounded injections | $199–$349/mo Recurring basis: $199 | Plan and dose dependent | No separate membership in advertised bundle | Medication, supplies, shipping and follow-up as stated | Provider-reported Checked July 12, 2026 |
| Found Multiple · Compounded and brand pathways | $169–$1,199/mo Recurring basis: $268 | Multi-month offers and membership tiers | Required program fee may be $99–$149/mo | Clinical coaching, insurance check and medication pathway | Provider-reported Checked July 12, 2026 |
| Mochi Health Tirzepatide · Weekly injection | $278/mo total Recurring basis: $278 | Month-to-month | $79/mo | $199 medication, physician and dietitian access, messaging and shipping | Primary source Checked July 12, 2026 |
| Noom Med Multiple · Medication plus behavioral program | $199–$299/mo Recurring basis: $279 | Offer dependent | Included where stated | Medication pathway and behavioral coaching | Secondary snapshot Checked July 12, 2026 |
| Enhance.MD Tirzepatide · Weekly injection — standard program | $280/mo Recurring basis: $280 | Plan terms apply | None stated | Medication, provider care, labs and lifestyle coaching | Primary source Checked July 12, 2026 |
| bmiMD Multiple · Injection and microdose programs | $289–$399/mo Recurring basis: $289 | Varies by program | No separate fee stated in captured offer | Telehealth review, medication, support and shipping as stated | Provider-reported Checked July 12, 2026 |
| Eden Tirzepatide · Weekly injection | $298/mo ongoing total Recurring basis: $298 | Monthly | $39 first month, then $99/mo | $199 medication plus required Eden membership | Provider-reported Checked July 12, 2026 |
| Hers Multiple · Brand and compounded pathways for women | $298–$2,048/mo Recurring basis: $298 | Varies | Program fee may apply | Telehealth care and medication pathway | Secondary snapshot Checked July 12, 2026 |
| Hims Multiple · Brand and compounded pathways for men | $298–$448/mo Recurring basis: $298 | Varies | Program fee may apply | Telehealth care and medication pathway | Secondary snapshot Checked July 12, 2026 |
| LillyDirect Tirzepatide · Zepbound KwikPen or single-dose vial | $299–$449/mo with refill terms Recurring basis: $299 | Monthly; $449 offer for 7.5–15 mg requires refill within 45 days | No required fee | Medication and delivery; clinical care not included | Primary source Checked July 12, 2026 |
| MEDVi Multiple · Compounded and brand pathways | $299–$399/mo Recurring basis: $299 | Varies | Split-fee structure may apply | Telehealth care and medication pathway | Provider-reported Checked July 12, 2026 |
| PlushCare Multiple · Insurance-first telehealth | $319–$1,120/mo cash-pay range Recurring basis: $319 | Membership plus medication/cost sharing | Membership and visit fees may apply | Physician access and prior-authorization support | Secondary snapshot Checked July 12, 2026 |
| NovoCare Pharmacy Semaglutide · Wegovy injection | $199 intro, then $349/mo Recurring basis: $349 | Two introductory fills; terms apply | No required fee | Medication and pharmacy fulfillment; clinical care not included | Primary source Checked July 12, 2026 |
| WeightWatchers Clinic Multiple · Brand medication plus behavioral program | $323–$423/mo Recurring basis: $373 | Monthly | Clinic/WW program fee included in estimate | Clinical care, app, workshops and medication pathway | Secondary snapshot Checked July 12, 2026 |
| Ro Multiple · Brand medications with insurance coordination | $348–$548/mo typical self-pay bundle Recurring basis: $448 | Monthly | Body Program fee applies | Clinical care, insurance concierge and medication pathway | Secondary snapshot Checked July 12, 2026 |
Reuse and interpretation
Rows are dated snapshots, not guaranteed future prices. Medication-only and all-inclusive offers are separate. Missing values are not inferred. Cite the provider, offer, evidence label and checked date together.
Operational standard
This policy is applied through a claim-level evidence ledger. Each material claim records the source, capture date, evidence class, reviewer and the pages that reuse it. Centralizing the record prevents a price or regulatory fact from being updated on one page while remaining stale elsewhere.
Pages are reviewed on a scheduled cadence and whenever a material trigger occurs: an FDA approval or warning, label change, new pivotal trial, shortage-status change, manufacturer pricing update, provider fee change, pharmacy disclosure change or substantiated correction. Cosmetic edits do not reset a clinical-review date.
Peptides Editorial distinguishes three forms of certainty. Verified means the current primary source directly supports the statement. Provider-reported means the company states the fact but additional facility, checkout or third-party confirmation may still be needed. Not normalized means the available evidence is insufficient for a comparative claim; the site does not fill the gap with an estimate.
Publication safeguards
- One visible H1 and one canonical URL per page.
- Answer-first summaries retain material qualifications, not just the favorable number.
- Medical efficacy is never inferred from a provider price, testimonial or receptor description.
- Compounded, investigational and FDA-approved products are labeled as different regulatory categories.
- Prices display the commitment, mandatory fees and evidence date in the same comparison context.
- Reviewer credentials and roles are stated narrowly; unsupported degrees, affiliations or licenses are not published.
- Corrections that alter rankings trigger recalculation across every dependent page.
Frequently asked questions
How are factual claims approved?
Claims are checked against the highest available source tier. Regulatory and safety statements use FDA records or official labeling; clinical-outcome statements use peer-reviewed primary research; prices use provider or manufacturer terms with a capture date.
Can a provider review or correct its page?
A provider may submit primary evidence and a written response. Editorial staff verifies the evidence and corrects material errors, but the provider does not approve the conclusion or buy a score.
Does medical review make this personal medical advice?
No. Medical review improves factual and clinical accuracy but does not evaluate an individual reader, create a clinician-patient relationship or replace emergency care.
How is AI used?
Automation may help organize source ledgers, detect inconsistencies and draft structured summaries. Final published claims, tables and conclusions remain subject to human editorial review and the same evidence standard.